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Abstract: Gliomas are intrinsic brain tumours, which are classified by the World Health Organization
(WHO) into different grades of malignancy, with glioblastoma being the most frequent and most malig-
nant subtype (WHO grade IV). Mutations in the isocitrate dehydrogenase (IDH) 1 or 2 genes are frequent
in lower (WHO II/III) grade tumours but typically absent in classical glioblastoma. IDH mutations are
associated with a better prognosis compared with IDH wild-type tumours of the same WHO grade. Fol-
lowing detection of a tumour mass by imaging, maximum safe surgery as feasible is commonly performed
to reduce mass effect and to obtain tissue allowing histopathological diagnosis and molecular assessment.
Radiotherapy has been the mainstay in the treatment of diffuse gliomas for several decades. It provides
improved local control, but is not curative. Furthermore, several randomised trials have shown that the
addition of alkylating chemotherapy, either temozolomide or nitrosourea-based regimens, to radiotherapy
results in prolonged survival. Tumour-treating fields (TTFields) have emerged as an additional treat-
ment option in combination with maintenance temozolomide treatment for patients with newly diagnosed
glioblastoma. Treatment at recurrence is less standardised and depends on the patientrsquo;s performance
status, symptom burden and prior treatments. Bevacizumab prolongs progression-free survival in newly
diagnosed and recurrent glioblastoma, but does not impact overall survival. However, in Switzerland and
some other countries, it is still considered a valuable treatment option to reduce clinical symptom burden.
Given the generally poor outcome for these patients, various novel treatment approaches are currently
being explored within clinical trials including immunotherapeutic strategies such as immune checkpoint
inhibition and the brain-penetrant proteasome inhibitor marizomib.
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